{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:21:40Z","timestamp":1784856100544,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Evaluation of safety and efficacy of desmopressin\/tolterodine combination therapy in women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This double\u2010blind, randomized, proof\u2010of\u2010concept study enrolled 106 patients (\u226518\u2009years), with overactive bladder (<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>) and nocturia, with \u22652 nocturnal voids, receiving a 3\u2010month once\u2010daily combination (desmopressin 25\u2009\u00b5g, orally\u2010disintegrating tablets [<jats:styled-content style=\"fixed-case\">ODT<\/jats:styled-content>]\/tolterodine 4\u2009mg [Detrol\u00ae <jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content>]; <jats:italic>n<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u200949) or monotherapy (tolterodine 4\u2009mg\/placebo <jats:styled-content style=\"fixed-case\">ODT<\/jats:styled-content>; <jats:italic>n<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u200957). Primary endpoint was change from baseline in mean number of nocturnal voids. Secondary endpoints were change from baseline in nocturnal voided volume, time to first nocturnal void, and quality\u2010of\u2010life. <jats:italic>Post\u2010hoc<\/jats:italic> exploratory analysis were performed for patients with and without baseline nocturnal polyuria (<jats:styled-content style=\"fixed-case\">NP<\/jats:styled-content>, <jats:italic>n<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u200947 each).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall population showed a non\u2010significant reduction in mean number of nocturnal voids with combination <jats:italic>versus<\/jats:italic> monotherapy (full analysis set: adjusted treatment contrast [<jats:styled-content style=\"fixed-case\">TC<\/jats:styled-content>], \u22120.34; <jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u20090.112). Change in mean nocturnal void volume (<jats:styled-content style=\"fixed-case\">TC<\/jats:styled-content>, \u221264.16\u2009mL; <jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u20090.103), mean time to first nocturnal void (<jats:styled-content style=\"fixed-case\">TC<\/jats:styled-content>, 18.00\u2009min; <jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u20090.385) and <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>octuria <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>mpact (<jats:styled-content style=\"fixed-case\">NI<\/jats:styled-content>) Diary<jats:sup>\u00a9<\/jats:sup> scores were comparable. In <jats:italic>post\u2010hoc<\/jats:italic> analysis, <jats:styled-content style=\"fixed-case\">NP<\/jats:styled-content> patients showed a benefit with combination <jats:italic>versus<\/jats:italic> monotherapy for nocturnal void volume (<jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u20090.034) and time to first nocturnal void (<jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u20090.045), and a non\u2010significant improvement in <jats:styled-content style=\"fixed-case\">NI<\/jats:styled-content> Diary<jats:sup>\u00a9<\/jats:sup> scores. Safety profile was comparable between treatments. A single transient event of asymptomatic clinically significant hyponatremia in combination group resolved subsequently.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Low\u2010dose desmopressin could be safely combined with tolterodine for treating nocturia in women with <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>, with a significant benefit in women with <jats:styled-content style=\"fixed-case\">NP<\/jats:styled-content>. Further, prospective validation studies of combination therapy are warranted in mixed <jats:styled-content style=\"fixed-case\">NP<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content> population, based on this favorable proof\u2010of\u2010concept finding.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12169","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T07:57:04Z","timestamp":1496217424000},"page":"221-230","source":"Crossref","is-referenced-by-count":30,"title":["Low\u2010dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double\u2010blind, Randomized, Controlled Study"],"prefix":"10.1111","volume":"10","author":[{"given":"Eric S.","family":"ROVNER","sequence":"first","affiliation":[{"name":"Department of Urology, Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"RAYMOND","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals  Copenhagen S Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"ANDRUCZYK","sequence":"additional","affiliation":[{"name":"Clinical Research of Philadelphia, LLC  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian V.","family":"JUUL","sequence":"additional","affiliation":[{"name":"Ferring Pharmaceuticals  Copenhagen S Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2013.54.2.95"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.04.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22585"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.108"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09972.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10175.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/GCO.0b013e32834ac78c","article-title":"Nocturia: current status and future perspectives","volume":"23","author":"Kerrebroeck P","year":"2011","journal-title":"Curr Opin Obstet Gynecol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02209.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-006-0239-y"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.05.083"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.061"},{"key":"e_1_2_6_14_1","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient\u2010reported outcomes from a randomized, double\u2010blind, factorial, dose\u2010ranging, Phase II study (SYMPHONY)","author":"Abrams P","year":"2016","journal-title":"World J Urol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10124.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2319"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-011-0054-3"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.03.095"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2010.25.12.1792"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0679-0"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22592"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.037"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1378-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02336.x"},{"key":"e_1_2_6_26_1","first-page":"57","article-title":"Combination therapies for the management of nocturia and its comorbidities","volume":"7","author":"Yazici CM","year":"2015","journal-title":"Res Rep Urol"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.06.007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10053"},{"key":"e_1_2_6_29_1","volume-title":"International Classification of Sleep Disorders: Diagnostic and Coding Manual","author":"American Academy of Sleep Medicine","year":"2005"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/15402002.2012.636267"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20093"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53260.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03724.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11736.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp133"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.03.080"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2010.04.014"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488607781668891"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:02:49Z","timestamp":1695009769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/luts.12169"],"URL":"https:\/\/doi.org\/10.1111\/luts.12169","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]}}}